WMS 2023 symposium: Connecting the dots: All-around care and evidence in Duchenne muscular dystrophy
This symposium, presented at WMS 2023, provides an overview of clinical trial and real-world data for nonsense mutation Duchenne muscular dystrophy (nmDMD) and examines the importance of all-around care for DMD
Understand the role of continuous corticosteroid therapy in DMD
Appreciate the totality of evidence for ataluren in the treatment of nmDMD
Get up to date with the latest clinical and real-world data for ataluren in patients with nmDMD
▼ Ataluren is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions via the national reporting system. Adverse events should also be reported to PTC at firstname.lastname@example.org.
Registration conditions differ internationally, and prescribing information may vary depending on local approval in each country. The European Summary of Product Characteristics for ataluren is available here. Please refer to your local country guidance for more information.
This symposium was developed and funded by PTC Therapeutics for WMS 2023.
Register now to unlock the content
Register now to access the content on this page
If not, register below
MED-ALL-DMD-2300195 | December 2023
Sign in or register to access exclusive content on this site